Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Ingrezza® Sprinkle (valbenazine) – New formulation approval
April 30, 2024 - Neurocrine Biosciences announced the FDA approval of Ingrezza Sprinkle (valbenazine) capsules, for the treatment of adults with Tardive dyskinesia or Chorea associated with Huntington’s disease.
